GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » EV-to-FCF

Aytu BioPharma (STU:AY20) EV-to-FCF : 10.65 (As of Mar. 31, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Aytu BioPharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aytu BioPharma's Enterprise Value is €6.47 Mil. Aytu BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €0.61 Mil. Therefore, Aytu BioPharma's EV-to-FCF for today is 10.65.

The historical rank and industry rank for Aytu BioPharma's EV-to-FCF or its related term are showing as below:

STU:AY20' s EV-to-FCF Range Over the Past 10 Years
Min: -8.07   Med: -0.39   Max: 19.8
Current: 5.5

During the past 13 years, the highest EV-to-FCF of Aytu BioPharma was 19.80. The lowest was -8.07. And the median was -0.39.

STU:AY20's EV-to-FCF is ranked better than
90.71% of 549 companies
in the Drug Manufacturers industry
Industry Median: 23.45 vs STU:AY20: 5.50

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-31), Aytu BioPharma's stock price is €1.76. Aytu BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.240. Therefore, Aytu BioPharma's PE Ratio (TTM) for today is At Loss.


Aytu BioPharma EV-to-FCF Historical Data

The historical data trend for Aytu BioPharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma EV-to-FCF Chart

Aytu BioPharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.67 -4.35 -0.88 -0.43 -9.05

Aytu BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 1.58 -9.05 -4.35 11.19

Competitive Comparison of Aytu BioPharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aytu BioPharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's EV-to-FCF falls into.


;
;

Aytu BioPharma EV-to-FCF Calculation

Aytu BioPharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6.465/0.607
=10.65

Aytu BioPharma's current Enterprise Value is €6.47 Mil.
Aytu BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aytu BioPharma  (STU:AY20) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Aytu BioPharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.76/-1.240
=At Loss

Aytu BioPharma's share price for today is €1.76.
Aytu BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Aytu BioPharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Aytu BioPharma Business Description

Traded in Other Exchanges
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines